All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Achievement of MDA with deucravacitinib in PsA: Results from a phase II trial
By Ella Dixon
|
Deucravacitinib is a novel TYK2 inhibitor that is approved for the treatment of psoriasis in multiple countries and is currently being investigated in PsA. A phase II, multicenter, double-blind trial (NCT03881059) evaluated the safety and efficacy of deucravacitinib in PsA. Patients were randomized 1:1:1 to deucravacitinib (6 mg or 12 mg) or placebo. A post-hoc analysis of this trial, published in Oxford Rheumatology, evaluated the achievement of MDA components through Week 16. Achievement of MDA is associated with improved outcomes and quality of life in patients with PsA. |
| Key learnings |
| Deucravacitinib was more effective than placebo in achieving MDA after 16 weeks, with 22.9% and 23.9% of patients treated with 6 mg and 12 mg deucravacitinib meeting MDA criteria compared with 7.6% of patients treated with placebo. |
| Deucravacitinib-treated patients showed improvement across MDA components, such as tender/swollen joint counts, patient-reported pain, and skin psoriasis (PASI score). All MDA responders met the tender entheseal points ≤1 criterion; however, 47.3% of patients had already met the criterion at baseline. |
| Improvements in several MDA components, including physical functioning and pain, were evident as early as 4 weeks after treatment initiation, indicating a rapid onset of action. |
| These findings suggest that deucravacitinib could be a viable alternative for patients who cannot achieve adequate disease control with existing PsA therapies, potentially improving both short- and long-term quality of life and function in these patients. |
Abbreviations: MDA, minimal disease activity; PASI, psoriasis area and severity index; PsA, psoriatic arthritis.
- Kavanaugh A, Coates LC, Mease PJ, et al. Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial. Rheumatology (Oxford). Online ahead of print. DOI: 10.1093/rheumatology/keae580
More about...
Your opinion matters
10 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox